• BactiQuant announced a corporate reorganization to align operations with its pharma-focused commercial strategy launched in March 2026.
• Headcount was reduced. Fixed operating expenses were cut 15% over the past six months.
• The company shifted resources toward pharma to accelerate recurring revenue growth, while maintaining activity in other segments.
• Management is targeting break-even on the back of the lower cost base.
• Sales capacity will be strengthened, with emphasis on direct selling to pharma manufacturing sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bactiquant A/S published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.